AURA

AURA

Aura Biosciences Inc

Net -5.84%top 1%Rev โ€”top 1%1Y
Hold

Aura Biosciences develops precision therapies using virus-like drug conjugates to target solid tumors. Its lead candidate, bel-sar, is in late-stage clinical trials for primary choroidal melanoma and is also exploring treatments for bladder cancer.

โš•๏ธ Healthcare NASDAQ Listed 2021 $ USD
$1,000 invested 1 year ago โ†’$1,117today

Score Overview

1 Year
Scoreโ€”
Net Growth-5.84%
Net TrendShrank
Net Income Consistencyโ€”
Rev Growthโ€”
Rev TrendShrank
Revenue Consistencyโ€”
All Time
Scoreโ€”
Net Growth-218.84%
Net TrendNever
Net Income Consistency
Rev Growthโ€”
Rev TrendNever
Revenue Consistency

See the full market ranking โ†’

Aura Biosciences Inc fundamental performance

Across Aura Biosciences Inc's full reported history, from 2021 to 2025, revenue held from $ 0.00 to $ 0.00 and net income went from -$ 35M to -$ 106M. Revenue increased in 0% of the years measured; net income in 0%.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-08-12
$ 7.75โ€”
1 Year2025-08-12
$ 6.9411.67%
All Time2021-10-29
$ 14.80-47.64%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Year
2026$ 0.00-$ 112M$ 114M
2025$ 0.00-$ 106M$ 144M
2024$ 0.00-$ 86M$ 151M
2023$ 0.00-$ 76M$ 226M
2022$ 0.00-$ 58M$ 188M
IPO2021$ 0.00-$ 35M$ 149M

Explore beyond AURA

You're looking at Aura Biosciences Inc. Members apply the same fundamental framework across all 3,860 companies we cover.

$99/year $149 founding price

Unlock Holder Dashboard

30-day money-back guarantee.

Explore other companies